Last edition
News about "Olumiant FDA approval"
US FDA Approves Olumiant for Pediatric Alopecia Areata
US FDA has approved Lilly’s Olumiant (baricitinib) for severe alopecia areata in patients aged 12 and older, based on the phase 3 BRAVE-AA-PEDS study.
Olumiant FDA Approval | 28/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members